{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:11:15Z","timestamp":1784214675041,"version":"3.55.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi260664-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed the management of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), yet most patients eventually develop resistance. Investigational immunotherapy strategies beyond checkpoint blockade are being explored, but their clinical activity and associated biomarkers remain poorly defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260664-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety, antitumor activity, and biomarkers associated with novel immunotherapy agents in patients with recurrent or metastatic HNSCC treated in early-phase clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260664-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study was conducted at The University of Texas MD Anderson Cancer Center Department of Investigational Cancer Therapeutics and included adult patients (aged \u226518 years) with advanced HNSCC treated with novel immunotherapy agents in early-phase clinical trials between January 1, 2015, and May 31, 2025. Patients were followed up from treatment initiation until disease progression, death, or last clinical contact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260664-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>Treatment with investigational immunotherapy agents administered in early-phase clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260664-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcomes included treatment-related adverse events, objective response rate (complete or partial response), clinical benefit rate (complete or partial response or stable disease lasting \u22656 months), progression-free survival, and overall survival. Logistic regression was used to evaluate biomarkers associated with the clinical benefit rate, including clinical, genomic, and treatment-related variables, while survival outcomes were estimated using the Kaplan-Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260664-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The sample included 158 patients (median [range] age, 60.7 [25.7-84.6] years; 136 male [86.1%]). The oropharynx was the most common primary site (94 patients [59.6%]). Patients had received a median of 3 prior lines (range, 0-8 prior lines) of systemic therapies, and 126 patients (79.7%) had prior ICI exposure. A total of 91 of 153 patients (59.5%) had human papillomavirus\u2013positive tumors, and\n                      <jats:italic toggle=\"yes\">PD-L1<\/jats:italic>\n                      combined positive score of at least 1 was observed in 67 of 87 patients (77.0%). Most patients received combination immunotherapy (106 [67.1%]), with a median treatment duration of 2.3 months (range, 0.1-19.7 months). Treatment-related adverse effects occurred in 85 patients (53.8%), including grade 3 or higher events in 23 patients (14.6%). The overall response rate was 7.7% (12 patients), and the clinical benefit rate was 16.1% (25 patients). Bispecific antibodies were associated with improved clinical benefit (odds ratio, 1.95; 95% CI, 1.23-4.15), whereas\n                      <jats:italic toggle=\"yes\">PIK3CA<\/jats:italic>\n                      alterations were associated with reduced benefit (odds ratio, 0.03; 95% CI, 0.00-0.51). Median progression-free survival was 2.3 months (95% CI, 2.0-2.9 months) and median overall survival was 8.3 months (95% CI, 7.2-11.0 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi260664-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This retrospective cohort study of heavily pretreated patients with HNSCC treated in early-phase clinical trials found that novel immunotherapy agents may have manageable toxic effects but modest antitumor activity. Bispecific antibodies may have encouraging activity while genomic alterations may help inform treatment stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.23522","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:00:51Z","timestamp":1784214051000},"page":"e2623522","source":"Crossref","is-referenced-by-count":0,"title":["Novel Immunotherapy Agents in Early-Phase Trials for Head and Neck Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Harold Nathan","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Mirallas","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed H.","family":"Derbala","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Salih","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilibeth","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina E.","family":"Dumbrava","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rod\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Champiat","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Akhave","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"1","key":"zoi260664r1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer.","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi260664r2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025.","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi260664r3","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study.","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260664r4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","article-title":"Resistance mechanisms to immune checkpoint inhibitors: updated insights.","volume":"24","author":"Alsaafeen","year":"2025","journal-title":"Mol Cancer"},{"key":"zoi260664r5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597202","article-title":"Unraveling the immune evasion mechanisms in the tumor microenvironment of head and neck squamous cell carcinoma.","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"zoi260664r6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI188128","article-title":"Immunotherapeutic strategies in head and neck cancer: challenges and opportunities.","volume":"135","author":"Liu","year":"2025","journal-title":"J Clin Invest"},{"issue":"6","key":"zoi260664r7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41388-023-02912-2","article-title":"Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway.","volume":"43","author":"Luo","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"zoi260664r8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"issue":"2","key":"zoi260664r9","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation.","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"zoi260664r10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-080222-100847","article-title":"Application and expectations for immune checkpoint blockade of LAG3 and TIGIT.","volume":"76","author":"Dumbrava","year":"2025","journal-title":"Annu Rev Med"},{"issue":"2","key":"zoi260664r11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.coi.2013.01.004","article-title":"The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.","volume":"25","author":"Moran","year":"2013","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"zoi260664r12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice.","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"zoi260664r13","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.3390\/cancers12092626","article-title":"Targeting myeloid-derived suppressor cells in cancer immunotherapy.","volume":"12","author":"Wang","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"zoi260664r14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy.","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"zoi260664r15","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy.","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi260664r16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy.","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"zoi260664r17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges.","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"zoi260664r18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy.","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"6230","key":"zoi260664r19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer.","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"issue":"6382","key":"zoi260664r20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer.","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"8","key":"zoi260664r21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline.","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"zoi260664r22","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"zoi260664r24","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-472792","article-title":"Bispecific antibodies in non-small cell lung cancer: from targeted innovation to real-world integration.","volume":"45","author":"Carlisle","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"30","key":"zoi260664r25","doi-asserted-by":"publisher","first-page":"47777","DOI":"10.18632\/oncotarget.10013","article-title":"Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.","volume":"7","author":"Lulli","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"zoi260664r26","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm.","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260664r27","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433330","article-title":"Breaking ground in recurrent or metastatic head and neck squamous cell carcinoma: novel therapies beyond PD-L1 immunotherapy.","volume":"44","author":"Rosenberg","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"zoi260664r28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596583","article-title":"Advances and challenges in immunotherapy in head and neck cancer.","volume":"16","author":"Aboaid","year":"2025","journal-title":"Front Immunol"},{"issue":"7","key":"zoi260664r29","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges.","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"zoi260664r30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy.","volume":"23","author":"Klein","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"zoi260664r31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology.","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"3","key":"zoi260664r32","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473148","article-title":"Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances.","volume":"45","author":"Guidi","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"zoi260664r33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12943-025-02390-y","article-title":"Bispecific antibodies: unleashing a new era in oncology treatment.","volume":"24","author":"Shui","year":"2025","journal-title":"Mol Cancer"},{"key":"zoi260664r34","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1200\/JCO.2025.43.16_suppl.6017","article-title":"Ficerafusp alfa with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: updated results from an expansion cohort of an open-label, multicenter, phase 1\/1b trial.","volume":"43","author":"Chung","year":"2025","journal-title":"J Clin Oncol"},{"key":"zoi260664r35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e17502","article-title":"Efficacy and safety of cadonilimab in recurrent\/metastatic solid tumors including ICI-treated tumors in clinical practice: cohorts of head and neck squamous cell carcinoma and cervical cancer.","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"zoi260664r36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1589243","article-title":"Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy.","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"zoi260664r37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes.","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"issue":"10","key":"zoi260664r38","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.ccell.2023.09.006","article-title":"Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.","volume":"41","author":"Zhu","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"zoi260664r39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003402","article-title":"PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.","volume":"10","author":"Collins","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"14","key":"zoi260664r40","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","article-title":"CDKN2A alterations and response to immunotherapy in solid tumors.","volume":"27","author":"Adib","year":"2021","journal-title":"Clin Cancer Res"},{"key":"zoi260664r41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1449291","article-title":"Lymphatic system regulation of anti-cancer immunity and metastasis.","volume":"15","author":"Lei","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"zoi260664r42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41392-023-01576-4","article-title":"Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions.","volume":"8","author":"Ji","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"zoi260664r43","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies.","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"issue":"6","key":"zoi260664r44","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"key":"zoi260664r23","volume-title":"R: A Language and Environment for Statistical Computing. Version 4.5.1","author":"R Core Team","year":"2021"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851707\/tan_2026_oi_260664_1783614596.75648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:00:53Z","timestamp":1784214053000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.23522","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}